High Viral Suppression with TLD in PEPFAR Programs — But Resistance and Adherence Signals Require Targeted Action
Posted inHIV/AIDS Infectious Diseases news

High Viral Suppression with TLD in PEPFAR Programs — But Resistance and Adherence Signals Require Targeted Action

A multinational prospective cohort found high viral suppression after switching or initiating tenofovir–lamivudine–dolutegravir (TLD), but emergent dolutegravir-resistance was detected in a small subgroup with prior virological failure and poor adherence, highlighting the need for monitoring and adherence support.
GanLum (KLU156): A New Class of Antimalarial Showing 97.4% PCR‑Corrected Cure in Phase III
Posted inInfectious Diseases news Public Health

GanLum (KLU156): A New Class of Antimalarial Showing 97.4% PCR‑Corrected Cure in Phase III

A Phase III trial of ganaplacide‑lumefantrine (GanLum, KLU156) met its primary non‑inferiority endpoint vs artemether‑lumefantrine, with a PCR‑corrected Day‑29 cure rate of 97.4% (estimand). The drug combines a novel mechanism (ganaplacide) with once‑daily lumefantrine and shows promise against partially resistant strains and gametocytes.